New hope for GIST: velzatinib takes on imatinib in major trial
NCT ID NCT07585266
First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This phase 3 trial compares a new drug, velzatinib, to the standard drug imatinib in 800 people with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The goal is to see if velzatinib can delay tumor growth better than imatinib. Participants have not had prior treatment for advanced GIST.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Velzatinib (a targeted drug) compared to imatinib (standard targeted drug)
- What this could lead to
- If velzatinib works better than imatinib, it could become a new first-line treatment that delays tumor growth longer for people with advanced GIST.
- What could go wrong
- This is an early-stage comparison; velzatinib may not prove superior or may have unexpected side effects. Results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Canton, Ohio, 44718, United States
-
GSK Investigational Site
Seoul, 138-736, South Korea